Abstract
Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor for which there are no screening methods sensitive enough to facilitate early, effective intervention. We propose targeting the neuroendocrine tumor neoantigen CD133 via antibody-based early detection and positron emission tomography (immunoPET) to facilitate the earlier and more accurate detection of SCLC. Methods: RNAseq datasets, IHC, flow cytometry, and western blots were used to quantify CD133 expression in healthy and SCLC patients. CD133 was imaged in vivo using near-infrared fluorescence immunoimaging and zirconium-89 immunoPET. Anti(α)-CD133 autoantibody levels were measured in SCLC patient plasma using antibody microarrays. Results: Across 6 publicly available datasets, CD133 mRNA was found to be higher in SCLC tumors compared to other tissues, including healthy or normal adjacent lung and non-SCLC samples. Critically, the upregulation of CD133 mRNA in SCLC was associated with a significant increase (HR 2.62) in death. CD133 protein was expressed in primary human SCLC, in SCLC patient-derived xenografts (PDXs), and in both SCLC cell lines tested (H82 and H69). Using a H82 xenograft mouse model, we first imaged CD133 expression with near-infrared fluorescence (NIRF). Both in vivo and ex vivo NIRF clearly show that a fluorophore-tagged αCD133 homed to lung tumors. Next, we validated the non-invasive visualization of subcutaneous and orthotopic H82 xenografts via immunoPET. An αCD133 antibody labeled with the positron-emitting radiometal zirconium-89 demonstrated significant accumulation in tumor tissue while producing minimal uptake in healthy organs. Finally, plasma αCD133 autoantibodies were found in subjects from cohort studies up to 1 year prior to SCLC diagnosis. Conclusion: In light of these findings, we conclude that the presence of αCD133 autoantibodies in a blood sample followed by CD133-targeted 89Zr-immunoPET could be an effective early detection screening strategy for SCLC.
- Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user